According to 2018Q4 Securities and Exchange form the Mawer Investment Management Ltd rose its holdings in Novartis Ag (NVS) by 53.37%. The company’s stock declined 0.59% while stock markets rallied as Mawer Investment Management Ltd bought 1.66M shares. The major pharmaceuticals company at the end of 2018Q4 was valued at $408.84 million. It’s up from 3.11M at the end of the previous reported quarter. Now it had 4.76M shares held by the institutional investor . $186.78 billion is the MC of Novartis Ag. The stock decreased 1.99% or $1.63 during the last trading session, hitting $80.24.Novartis AG is uptrending after having risen 8.33% since April 14, 2018. NVS has 4.44 million volume or 80.37% up from normal. NVS outperformed by 3.96% the S&P 500.

According to a filing Mawer Investment Management Ltd decreased its stake in Insperity Inc (NYSE:NSP) by 160,900 shares to 279,900 shares, valued at $26.13M in 2018Q4. The fund operates about $20.93 billion and $12.05 billion US Long portfolio. Mawer Investment Management Ltd has cut its stake in Fox Factory Holding Corp (NASDAQ:FOXF) and also reduced its holding in Cinemark Holdings Inc (NYSE:CNK) by 1.28M shares in the quarter, for a total of 558,224 shares.

For more Novartis AG (NYSE:NVS) news posted recently go to: Benzinga.com, Benzinga.com, Seekingalpha.com, Seekingalpha.com or Bizjournals.com. The titles are as follows: “Daily Biotech Pulse: Merck’s Keytruda Clinches Another FDA Win, KemPharm Close To NDA Filing For ADHD Drug – Benzinga” posted on April 12, 2019, “(ACB), Anheuser-Busch Inbev SA (NYSE:BUD) – For Cannabis Industry Investment, 2018 Was Terrific But 2019 Looks Even Better – Benzinga” on April 01, 2019, “Novartis And Tropifexor In NASH, And The Market Assessment – Seeking Alpha” with a publish date: April 09, 2019, “Novartis to face lawsuit over doctor kickbacks – Seeking Alpha” and the last “BioMed Realty plants flag in East Bay with acquisition of Novartis site – San Francisco Business Times – San Francisco Business Times” with publication date: March 20, 2019.

Novartis AG (NYSE:NVS) Ratings Coverage

Total analysts of 3 have positions in Novartis (NYSE:NVS) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 19, 2018 according to StockzIntelligence Inc Novartis has 6 analyst reports. On Monday, November 26 Cowen & Co upgraded Novartis AG (NYSE:NVS) to “Outperform” rating. On Tuesday, December 11 the firm earned “Buy” rating by Jefferies. On Monday, November 19 the firm earned “Conviction Buy” rating by Goldman Sachs.